GPC3 and CD16 levels in circulating immune cells could predict the efficacy of the drug when increasing codrituzumab exposure, according to a recent double-blind, phase II trial of GC33 in 185 patients with chemotherapy-unresponsive HCC. This evidence concerns the gene GPC3 and hepatocellular carcinoma.